Compare INSM & AVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | AVB |
|---|---|---|
| Founded | 1988 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 25.7B |
| IPO Year | 2000 | 1995 |
| Metric | INSM | AVB |
|---|---|---|
| Price | $109.08 | $180.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 15 |
| Target Price | ★ $201.17 | $198.40 |
| AVG Volume (30 Days) | ★ 3.2M | 814.7K |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | N/A | ★ $3,040,725,000.00 |
| Revenue This Year | $182.31 | $4.04 |
| Revenue Next Year | $65.19 | $5.03 |
| P/E Ratio | ★ N/A | $78.68 |
| Revenue Growth | N/A | ★ 4.36 |
| 52 Week Low | $64.85 | $160.10 |
| 52 Week High | $212.75 | $209.86 |
| Indicator | INSM | AVB |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 51.62 |
| Support Level | N/A | $174.32 |
| Resistance Level | $166.81 | $181.72 |
| Average True Range (ATR) | 8.04 | 3.52 |
| MACD | -1.61 | -0.38 |
| Stochastic Oscillator | 24.48 | 33.39 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.